| Status | Study |
| Not yet recruiting |
Study Name: Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Condition: Anemia B-Cell Prolymphocytic Leukemia Date: 2017-01-03 Interventions: Drug: Entospletinib Given PO |
| Recruiting |
Study Name: Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Condition: B-cell Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia Date: 2016-09-14 Interventions: Biological: XmAb13676 Biological |
| Recruiting |
Study Name: PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Condition: Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Fo Date: 2016-09-02 Interventions: Biological: anti-CD19 CAR-NK cells The allogeneic NK cells (NK-92 cell line for clinical use) are engine |
| Recruiting |
Study Name: Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Condition: Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Fo Date: 2016-07-28 Interventions: Biological: PCAR-019 (anti-CD19 CAR-T cells) Other Name: chimeric antigen receptor T cells with specific |
| Recruiting |
Study Name: CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Condition: Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Fo Date: 2016-06-28 Interventions: Biological: PCAR-019 (anti-CD19 CAR-T cells) Other Name: chimeric antigen receptor T cells with specific |
| Recruiting |
Study Name: Registry of the German CLL Study Group Condition: CLL SLL HCL Richter´ Date: 2015-02-26 |
| Withdrawn |
Study Name: Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML Condition: Lymphoproliferative Malignancies Acute Myeloid Leukemia Date: 2014-08-28 Interventions: Drug: ZEN003365 |
| Active, not recruiting |
Study Name: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia Condition: Post-transplant Lymphoproliferative Disorder B-Cell Prolymphocytic Leu Date: 2014-05-30 Interventions: Drug: cyclophosphamide Given I |
| Recruiting |
Study Name: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Condition: B-Cell Prolymphocytic Leukemia Recurrent Chronic Lymphocytic Le Date: 2013-06-24 Interventions: Drug: Ibrutinib Given PO |
| Active, not recruiting |
Study Name: PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia Condition: Prolymphocytic Leukemia Recurrent Small Lymphocytic Lymphoma Date: 2012-04-23 Interventions: Drug: ibrutinib Patients recei |